Last reviewed · How we verify

L-PZQ ODT

Merck KGaA, Darmstadt, Germany · Phase 1 active Small molecule

L-PZQ ODT is a Small molecule drug developed by Merck KGaA, Darmstadt, Germany. It is currently in Phase 1 development. Also known as: MSC 2499550A.

At a glance

Generic nameL-PZQ ODT
Also known asMSC 2499550A
SponsorMerck KGaA, Darmstadt, Germany
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about L-PZQ ODT

What is L-PZQ ODT?

L-PZQ ODT is a Small molecule drug developed by Merck KGaA, Darmstadt, Germany.

Who makes L-PZQ ODT?

L-PZQ ODT is developed by Merck KGaA, Darmstadt, Germany (see full Merck KGaA, Darmstadt, Germany pipeline at /company/merck-kgaa-darmstadt-germany).

Is L-PZQ ODT also known as anything else?

L-PZQ ODT is also known as MSC 2499550A.

What development phase is L-PZQ ODT in?

L-PZQ ODT is in Phase 1.

Related